GlassScriptPhysician profile
Reid S Christopher
NPI 1609978964
$3,556.10
in general payments reported to CMS, 2019-2025
21 companies · $747 in 2025
The $747 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $526 · 2021: $267 · 2022: $621 · 2023: $639 · 2024: $399 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.61 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $986.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $402.74 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $382.28 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $357.40 | 2022-2025 | |
| Glaxosmithkline, LLC. | $352.35 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $197.11 | 2019-2025 | |
| Lilly USA, LLC | $146.27 | 2022-2025 | Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $135.75 | 2020-2024 | Trintellix |
| Corcept Therapeutics | $104.23 | 2019-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $97.70 | 2020-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $82.32 | 2019-2022 | |
| Sk Life Science, INC. | $49.21 | 2025 | |
| Abbvie INC. | $45.74 | 2022 | |
| Antares Pharma, INC. | $38.65 | 2022 | |
| Abbott Laboratories | $37.91 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $34.19 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $29.81 | 2023 | Evkeeza |
| Amarin Pharma, INC. | $28.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.98 | 2020 | |
| Mylan Specialty L.P. | $14.87 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reid Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.